13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • South Australia - Melanoma & other skin

    Research> Current clinical trials> Melanoma & other skin

    Every day researchers work towards finding new breakthroughs in cancer. Clinical trials play a pivotal role in bringing that defeat closer.

    Clinical trials test promising new treatments on people to see if they are better than existing cancer treatments. The trial process is long starting many years before an actual treatment can be used.

    By joining a clinical trial you are helping to create new breakthroughs in cancer research. Hundreds of thousands of people all over the world have taken part in clinical trials that have lead to safer and more effective treatments for many cancers.

    It is important to note that not all cancer patients are eligible to take part in clinical trials and there are not clinical trials for all types of cancer.

    You may decide to join a clinical trial because:

    • The treatment you receive will be at least the best available for your illness.
    • Your health may improve because of the treatment you receive.
    • You may receive a treatment you would not otherwise have access to.
    • Your health will be carefully checked by the treatment team running the trial.
    • You will be part of the worldwide effort to improve cancer treatment.

    For more information on clinical trials please click here.

    Clinical trial managers:

    If you would like information regarding any of the below clinical trials, please contact the appropriate Clinical trials manager:

    Ashford Cancer Centre: Helen Daykin, +61 8 8292 2240

    Flinders Medical Centre: Alex Scott-Hoy, +61 8 8204 4830

    The Queen Elizabeth:  Sue Yeend, +61 8 8222 6148

    Lyell McEwin Hospitals: Julie Rowe or Rohit Joshi +61 8 8282 0833

    Royal Adelaide Hospital: Anne Milton, +61 8 7074 2342

    Current clinical trials for melanoma & other skin cancer

    Status Description Organisation
    Recruiting A Phase Iii, Double-Blinded, Randomized, Placebo-Controlled Study Of Atezolizumab Plus Cobimetinib And Vemurafenib Versus Placebo Plus Cobimetinib And Vemurafenib In Previously Untreated Brafv600 Mutation−Positive Patients With Unresectable Locally Advanced Or Metastatic Melanoma. Protocol: Triplet C039262 Royal Adelaide Hospital
    Recruiting A Phase 3, randomized study of adjuvant immunotherapy with nivolumab combined with ipilimumab versus ipilimumab or nivolumab monotherapy after complete resection of stage IIIb/c/d or stage IV melanoma. Royal Adelaide Hospital
    Recruiting CARPETS - A phase 1 parallel group study of the safety and immune effects of an escalating dose of autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells in patients with GD2-positive metastatic melanoma and refractory solid tumors. Royal Adelaide Hospital
    Recruiting Checkmate 401 (Melanoma) Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Flinders Medical Centre
    Not yet recruiting DV3- MEL-01 A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Ashford Cancer Centre
    Not Yet Recruiting FLIGHT An Open Label Phase 1 Study Investigating the Effects of CDX-301 on the Safety, Clinical Activity, and Immune Priming of Glembatumumab Vedotin Combined with Pembrolizumab or Nivolumab in Unresectable or Metastatic Melanoma Patients Not Responding to the AntiPD1 Therapy Royal Adelaide Hospital
    Not yet recruiting A Phase II Randomized, open-label, Multi-centre study of the safety and efficacy of IMCgp100 compared with Investigator choice in HLA-A*0201 positive patients with previously untreated advanced uveal melanoma. Royal Adelaide Hospital
    Recruiting KEYNOTE 29 A Phase 1/2, Clinical Trial to Study the Safety & Tolerability of MK3475 + Pegylated Interferon alfa-2b (PEG-IFN) & MK-3475 + Ipilimumab (IPI) in subjects with advanced Melanoma Royal Adelaide Hospital
    Recruiting MASTERKEY-265 - A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma The Queen Elizabeth Hospital
    Recruiting TACTI mel TACTI-mel (Two ACTive Immunotherapeutics in melanoma): A multicentre, open label, dose escalation, Phase 1 study in patients with unresectable or metastatic melanoma receiving IMP321 (LAG- 3Ig fusion protein) as an adjunctive therapy to anti-PD-1 therapy with pembrolizumab Flinders Medical Centre
    Recruiting TROG 08/09 - A randomized trial of post operative radiation therapy following wide excision of neurotropic melanoma of the head and neck Royal Adelaide Hospital

    Today at Cancer Council SA

  • Do you have a cancer question?

    Do you have a cancer question?

    Cancer causes questions. Call us for the answers.

  • Donate in lieu of flowers

    Donate in lieu of flowers

    Remembering loved ones by ensuring no one goes through cancer alone.

  • Fundraising events

    Fundraising events

    We have a wide range of exciting events that give you the opportunity to support our vision of a cancer free future in a fun, easy yet symbolic way.

  • Healthy Living after Cancer

    Healthy Living after Cancer

    Getting back to a healthy lifestyle after cancer is one of the most important things you can do for your health. Find out about our Healthy Living after Cancer program.

  • Heard something about cancer and not sure if it's true?

    Heard something about cancer and not sure if it's true?

    Get all the evidence based answers to your cancer questions here.

  • Join the conversation

    Join the conversation

    Follow us on Facebook to stay up to date with the latest community events and news.

  • More than a gift, it's hope for the future

    More than a gift, it's hope for the future

    Including a bequest to Cancer Council SA in your will is not an alternative to looking after your loved ones, it’s part of it. Find out more.

  • Quitline


    Quitline is a government-funded service operated by Cancer Council SA, with the sole goal of providing the support, strategies and information to empower individuals to quit smoking.